Drug Security Forum

Under the pressure of overwhelming circumstances, constituted by the COVID-19 pandemic and subsequent isolation, a number of industries had to expedite their transition to new operating environment. Healthcare was no exception and transformation of the industry to principles of patient-focusing began in next to no time. The pharma business, solving the problems of quick and continuous access to drug treatment, has put patients’ interests as the foundation for adaptation of its business models. In the course of carrying out the project to ensure remote delivery of drugs, pharma companies have spared no effort to ensure continuity of the new service. An infrastructure was created that needed to comply with requirements established by the government of the Russian Federation to counter dishonest suppliers; drug labelling was introduced; special facilities were equipped for storage of reserved drugs, and courier departments were created. Right now, there is talk of switching to a system of drug reimbursement. Regardless of the reimbursement model chosen, it is already clear that the social role that the pharma business plays will increase, which will take it from the service provider category to the rank of a coequal partner. And in the event of successful cooperation between the government and business, there is an opportunity for carrying out new and even larger joint projects. How specifically can the pharma business help in implementing government social projects involving drug supply? Is the industry ready for increased social responsibility? Patient focus is one of the key trends in the medical industry in recent years. How can pharma companies promote its integration in the healthcare system? What patient support programmes have become noticeable on the global market? The essence of the pharma business is in providing socially significant services by supplying the population with drugs. Where is the line between business and charity? The COVID-19 epidemic demonstrated that given reduction of the regulatory load, national pharma companies are capable of fully satisfying the demand of the population for drug access. What is the potential today for statutory accommodation of negotiations processes between the regulators and business?

Moderator
Yekaterina Gracheva, Anchor, Russia 24 TV Channel

Yekaterina Gracheva

Anchor, Russia 24 TV Channel

Panellists
Hans Duijf, Vice-President, Russia and Belarus, Novo Nordisk
Maria-Anna Laemmli, President, Swiss Health Touris; Publisher, Swiss Health Magazine
Akthem Fourati, Chief of Medicines and Nutrition Centre of Supply Division, United Nations Children's Fund (UNICEF)
Stephan Eder, Executive Vice President, STADA Russia-CIS

Hans Duijf

Vice-President, Russia and Belarus, Novo Nordisk

Hans Duijf was appointed Vice President of Novo Nordisk in Russia and Belarus since September 1, 2017.
Mr. Duijf is a Dutch national, born in June 1974. He moved to Moscow with his family, wife and two daughters, from Colombia, where he held the position of General Manager of the Novo Nordisk affiliate since 2015.
Mr. Duijf has nearly 20 years of experience in the affiliates and regional headquarters of Novo Nordisk in established and developing markets in Europe, South-East Asia and Latin America. Under his leadership diverse teams of different cultures consistently succeeded in improving performance and introducing innovative approaches. Mr. Duijf began his career in sales and marketing in the UK, and later participated in the product launching in the markets of different countries. He has extensive management experience in positions such as Marketing Director, Business Development Director, General Manager, Vice President.
Hans Duijf has received education in international marketing and strategic management and holds a Master of Science (M.Sc.) degree in Business Administration from Rotterdam School of Management, Erasmus University in the Netherlands.

Maria-Anna Laemmli

President, Swiss Health Touris; Publisher, Swiss Health Magazine

Akthem Fourati

Chief of Medicines and Nutrition Centre of Supply Division, United Nations Children's Fund (UNICEF)

Stephan Eder

Executive Vice President, STADA Russia-CIS

Front row participants
Yuriy Zhulev, President, Russian Hemophilia Society
Vitaliy Omelyanovskiy, General Director, Center for Healthcare Quality Assessment and Control of the Ministry of Health of the Russian Federation
Sean Reilly, Vice President, General Director, GSK
Mikhail Tsyferov, President, Member of the Board of Directors, Petrovax Pharm

Yuriy Zhulev

President, Russian Hemophilia Society

In 1985, graduated from the school number 856 (Moscow).
In 1991, graduated from the Moscow State Law University.
In 1989, he was elected Vice President of Hemophilia Association (later renamed Hemophilia Society) that was established the same year.
Since 1993, he was the President of the Hemophilia Society.
In 2000, at the founding congress of the Russian Hemophilia Society he was elected its President, and he still holds this position.
In 2002–2004, he was a board member of the European Hemophilia Consortium and member of the World Federation of Hemophilia. He was named ‘Best volunteer’ of the World Federation of Hemophilia for his active work in CIS countries.
At present, he also holds the following positions:
• Co-chairman of the Russian Union of Patients Public Societies;
• Member of Commission for the Disabled under President of the Russian Federation;
• Head of the working group for improvement of the state sociomedical assessment system and monitoring of implementation of decisions made for the Commission for the Disabled under President of the Russian Federation;
• Co-chair of the Council of public agencies for patients’ rights for the Ministry of Health of the Russian Federation;
• Deputy Chairman of the Public Council of the Ministry of Health of the Russian Federation;
• Member of Council of public agencies for patients’ rights for Federal Service for Surveillance in Healthcare;
• Member of Moscow’s regional department of All-Russia People's Front.
Yury Zhulyov was awarded with an honorary certificate by the Ministry of Health of the Russian Federation, an honorary certificate by the Federal Service for Surveillance in Healthcare and Social Development.

Vitaliy Omelyanovskiy

General Director, Center for Healthcare Quality Assessment and Control of the Ministry of Health of the Russian Federation

Born July 27, 1964 in Obninsk, Kaluga Oblast.
In 1987, he graduated from the Pirogov Russian National Research Medical University with a degree in General Medicine. After graduation he stayed in the university, where he rose from postgraduate to professor of the department of clinical pharmacology.
In 1998 he graduated from the Russian Presidential Academy of National Economy and Public Administration of the Russian Federation with a degree in state and municipal management, with the qualification of economist-financier.
In 2002, he defended the first doctoral dissertation in the Russian Federation on clinical and economic analysis and pharmacoeconomics.
From 2009 to 2012 he was. - Vladimir Potanin was Director of the Research Institute for Clinical and Economic Expertise and Pharmacoeconomics at the N.I. Pirogov Russian National Research Medical University, Federal State Autonomous Educational Institution of Higher Professional Education, Ministry of Health Care of the Russian Federation.
From 2012 to 2020, she was Head of the Research Laboratory of the N.I. Pirogov Russian National Research Medical University. - Head of the Research Laboratory for Technology Assessment in Healthcare at the Institute of Applied Economic Research of the Russian Presidential Academy of National Economy and Public Administration, a federal state budget-funded educational institution of higher education.
Since 2014. - Head of the Healthcare Finance Center of the Federal State Budgetary Institution "Research Financial Institute" of the Ministry of Finance of the Russian Federation. Ministry of Finance of the Russian Federation.
Since 2015. - General Director of the Federal State Budgetary Institution "Center for Expertise and Quality Control of Medical Care" of the Ministry of Health of the Russian Federation.
Since 2020. - Head of the Department of Economics, Management and Assessment of Healthcare Technologies of the Federal State Budgetary Educational Institution of Additional Professional Education "Russian Medical Academy of Continuing Professional Education" of the Ministry of Healthcare of the Russian Federation.

Member of the Dissertation Council D 208.088.01.
Head of the Expert Council on Health Care of the Federation Council Committee on Social Policy, Expert of the Analytical Centre for the Government of the Russian Federation.
Chief Clinical Pharmacologist, Ministry of Health, Moscow Region.
Chief editor of scientific journals, Pharmacoeconomics. Modern Pharmacoeconomics and Pharmacoepidemiology" and "Medical Technology. Evaluation and Choice".
She is an author of three patents of the Russian Federation, two monographs, educational and methodical manuals for physicians, and more than 140 scientific papers published in Russian and foreign medical journals.
Doctor of Medicine (2002), Professor (2007). Under his supervision V.V. Omelyanovsky defended one doctoral thesis and seven Ph. Currently supervises the theses of two doctoral students and two doctoral candidates.
He is the President of the Russian branch of the International Society for Pharmacoeconomic Research and Outcome Evaluation (ISPOR).
He is a laureate of the Russian Federation Government Award in Science and Technology, has certificates of merit from the President of the Russian Federation and the Chairman of the Federation Council of the Federal Assembly of the Russian Federation, and has received commendations from the Chairman of the Federation Council of the Federal Assembly of the Russian Federation, the Analytical Center of the Russian Federation Government, the Russian Academy of National Economy and Public Administration under the President of the Russian Federation, and the Sverdlovsk Oblast Government.

Sean Reilly

Vice President, General Director, GSK

Mikhail Tsyferov

President, Member of the Board of Directors, Petrovax Pharm

Before joining Petrovax in 2018, Mikhail Tsyferov gained extensive experience in a number of large investment companies.
From 2018 to present – President of NPO Petrovax Pharm LLC (part of the Interros Group), Member of the Board of Directors.
From 2016 to present – Managing Director of the Winter Capital Fund.
From 2008 to 2016 – manager of the investment department of Interros.
From 2007 to 2008 – employee of the capital markets department at Renaissance Capital.
Acted as an investor in more than 20 Private equity / VC transactions.
He graduated from the School of International Economic Relations of MGIMO (Moscow State Institute of International Relations) in 2007.